SCHEMBL2221990

SCHEMBL2221990

CC(C)OC(=O)c1cccnc1N1CCN(Cc2ccc(NC(=O)c3ccccc3)cc2)CC1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 9/20 0.55
SMN1; SMN2 Q16637 5/20 0.55
MAPK1 P28482 2/20 0.55
L3MBTL1 Q9Y468 3/20 0.54
KDM4E B2RXH2 3/20 0.54
POLB P06746 1/20 0.54
NPSR1 Q6W5P4 1/20 0.54
LMNA P02545 4/20 0.53
HSD17B10 Q99714 4/20 0.53
KMT2A Q03164 1/20 0.53
HIF1A Q16665 5/20 0.51
EPAS1 Q99814 5/20 0.51
ALDH1A1 P00352 2/20 0.49
USP2 O75604 1/20 0.49
HPGD P15428 1/20 0.49
TSHR P16473 2/20 0.48
NPC1 O15118 1/20 0.48
HTT P42858 1/20 0.48
RAB9A P51151 1/20 0.48
TP53 P04637 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2222628 0.90 MAPT (0.54) MAPTSMN1; SMN2MAPK1L3MBTL1KDM4E
SCHEMBL2221835 0.90 MAPT (0.53) MAPTSMN1; SMN2MAPK1L3MBTL1KDM4E
SCHEMBL2224197 0.90 MAPT (0.62) MAPTSMN1; SMN2MAPK1L3MBTL1KDM4E
SCHEMBL14632680 0.89 MAPT (0.51) MAPTSMN1; SMN2MAPK1L3MBTL1KDM4E
SCHEMBL2221551 0.88 MAPT (0.66) MAPTL3MBTL1KDM4EPOLBNPSR1
SCHEMBL2222557 0.87 MAPT (0.59) MAPTSMN1; SMN2L3MBTL1KDM4EPOLB
SCHEMBL12517212 0.87 MAPT (0.59) MAPTSMN1; SMN2MAPK1L3MBTL1KDM4E
SCHEMBL12517207 0.87 MAPT (0.59) MAPTSMN1; SMN2MAPK1L3MBTL1KDM4E
SCHEMBL2353100 0.87 MAPT (0.59) MAPTL3MBTL1KDM4EPOLBNPSR1
SCHEMBL2221133 0.86 MAPT (0.56) MAPTSMN1; SMN2MAPK1L3MBTL1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2523665-A1 VOLTAGE-GATED SODIUM CHANNEL BLOCKERS Glaxo Group Limited (GB) 2012-11-21 EP claimed
WO-2011088201-A1 VOLTAGE-GATED SODIUM CHANNEL BLOCKERS GLAXO GROUP LIMITED (GB) 2011-07-21 WO claimed
EP-2729149-A1 VOLTAGE-GATED SODIUM CHANNEL BLOCKERS Glaxo Group Limited (GB) 2014-05-14 EP disclosed
US-20140121213-A1 VOLTAGE-GATED SODIUM CHANNEL BLOCKERS GLAXO GROUP LIMITED (GB) 2014-05-01 US disclosed
US-20140121213-A1 VOLTAGE-GATED SODIUM CHANNEL BLOCKERS GLAXO GROUP LIMITED (GB) 2014-05-01 US disclosed
US-20130023541-A1 VOLTAGE-GATED SODIUM CHANNEL BLOCKERS GLAXO GROUP LIMITED 2013-01-24 US disclosed
US-20130023541-A1 VOLTAGE-GATED SODIUM CHANNEL BLOCKERS GLAXO GROUP LIMITED 2013-01-24 US disclosed
WO-2013006596-A1 VOLTAGE-GATED SODIUM CHANNEL BLOCKERS GLAXO GROUP LIMITED (GB) 2013-01-10 WO disclosed
WO-2013006596-A1 VOLTAGE-GATED SODIUM CHANNEL BLOCKERS GLAXO GROUP LIMITED (GB) 2013-01-10 WO disclosed
EP-2523665-A1 VOLTAGE-GATED SODIUM CHANNEL BLOCKERS Glaxo Group Limited (GB) 2012-11-21 EP disclosed
WO-2011088201-A1 VOLTAGE-GATED SODIUM CHANNEL BLOCKERS GLAXO GROUP LIMITED (GB) 2011-07-21 WO disclosed
WO-2011088201-A1 VOLTAGE-GATED SODIUM CHANNEL BLOCKERS GLAXO GROUP LIMITED (GB) 2011-07-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130023541-A1 VOLTAGE-GATED SODIUM CHANNEL BLOCKERS KCNB1, KCNB2, SCNN1B MAPT 1880/4885SMN1; SMN2 1087/4885MAPK1 3572/4885
US-20140121213-A1 VOLTAGE-GATED SODIUM CHANNEL BLOCKERS KCNB1, SCNN1B, TRPV1 MAPT 2771/4885SMN1; SMN2 1295/4885MAPK1 3555/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.